The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors
Open accessAbstract
Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also called the fibronectin receptor, in solid tumors. We summarize data showing that α5β1 integrin is a pertinent therapeutic target expressed by tumoral neovessels and tumoral cells. Although mainly evaluated in preclinical models, α5β1 integrin merits interest in particular in colon, breast, ovarian, lung and brain tumors where its overexpression is associated with a poor prognosis for patients. Specific α5β1 integrin antagonists will be listed that may represent new potential therapeutic agents to fight defined subpopulations of particularly aggressive tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barczyk, M., Carracedo, S., & Gullberg, D. (2010) · Cell and Tissue Research · doi:10.1007/s00441-009-0834-6 · Cited by 1,512
The final steps of integrin activation: the end game
Shattil, S. J., Kim, C., & Ginsberg, M. H. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2871 · Cited by 1,086
Integrins and Extracellular Matrix in Mechanotransduction
Schwartz, M. A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005066 · Cited by 662
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A., Kienast, Y., Vettel, C., Loos, E. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58832 · Cited by 479
Burleson, K. M., Casey, R. C., Skubitz, K. M., Pambuccian, S. E., Oegema, T. R., & Skubitz, A. P. N. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.034 · Cited by 269
Nam, J.-M., Onodera, Y., Bissell, M. J., & Park, C. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2319 · Cited by 196
Cited by
Thermoresponsive polymer nanocarriers for biomedical applications
Bordat, A., Boissenot, T., Nicolas, J., & Tsapis, N. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.005 · Cited by 415
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Saatci, O., Kaymak, A., Raza, U., Ersan, P. G., Akbulut, O., Banister, C. E., Sikirzhytski, V., Tokat, U. M., Aykut, G., Ansari, S. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16199-4 · Cited by 368
Angiogenesis in pancreatic cancer: current research status and clinical implications
Li, S., Xu, H.-X., Wu, C.-T., Wang, W.-Q., Jin, W., Gao, H.-L., Li, H., Zhang, S.-R., Xu, J.-Z., Qi, Z.-H., et al. (2019) · Angiogenesis · doi:10.1007/s10456-018-9645-2 · Cited by 284
Active targeting drug delivery nanocarriers: Ligands
Salahpour Anarjan, F. (2019) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2019.100370 · Cited by 196
3D scaffolds in breast cancer research
Rijal, G., & Li, W. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.016 · Cited by 169
Metadata
- Authors
- Schaffner, F., Ray, A., & Dontenwill, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2013-01-15
- Volume
- 5
- Issue
- 1
- Pages
- 27-47
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2028039139
- Cited by
- 225
- References
- 6
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. https://app.cochat.ai/papers/10.3390/cancers5010027
- The paper
- Schaffner, F., Ray, A., & Dontenwill, M. (2013). Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers. https://doi.org/10.3390/cancers5010027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.